Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Harvard Business School
Fish and Richardson
Covington
Federal Trade Commission
QuintilesIMS
Chinese Patent Office
Boehringer Ingelheim
Moodys

Generated: June 20, 2018

DrugPatentWatch Database Preview

TRITEC Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Tritec patents expire, and what generic alternatives are available?

Tritec is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in TRITEC is ranitidine bismuth citrate. There are forty-three drug master file entries for this compound. Additional details are available on the ranitidine bismuth citrate profile page.
Summary for TRITEC
US Patents:0
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for TRITEC
DailyMed Link:TRITEC at DailyMed
Drug patent expirations by year for TRITEC

US Patents and Regulatory Information for TRITEC

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for TRITEC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline TRITEC ranitidine bismuth citrate TABLET;ORAL 020559-001 Aug 8, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Colorcon
Mallinckrodt
Cipla
Fuji
McKesson
Chubb
QuintilesIMS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
 
Links

Follow DrugPatentWatch: